{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:27:59Z","timestamp":1793190479920,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","sleep.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine Clinics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jsmc.2025.06.004","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T19:28:18Z","timestamp":1752607698000},"page":"389-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacological Management of Insomnia in Parkinson\u2019s Disease"],"prefix":"10.1016","volume":"20","author":[{"given":"Karolina Pop\u0142awska","family":"Domaszewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Metta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosabel","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Falup-Pecurariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kit","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jsmc.2025.06.004_bib1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/mds.10167","article-title":"Sleep disorders in Parkinson\u2019s disease","volume":"17","author":"Kumar","year":"2002","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.jsmc.2025.06.004_bib2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/00002826-198812000-00004","article-title":"The nighttime problems of parkinson\u02bcs Disease","volume":"11","author":"Lees","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jsmc.2025.06.004_bib3","article-title":"Prodromal parkinson\u2019s disease","author":"Iro","year":"2025","journal-title":"Neurol Clin"},{"key":"10.1016\/j.jsmc.2025.06.004_bib4","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.parkreldis.2015.09.027","article-title":"Non motor subtypes and Parkinson\u2019s disease","volume":"22","author":"Sauerbier","year":"2016","journal-title":"Parkinsonism Relat Disorders"},{"key":"10.1016\/j.jsmc.2025.06.004_bib5","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-020-00894-7","article-title":"Therapy of parkinson\u2019s disease subtypes","author":"Marras","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.jsmc.2025.06.004_bib6","doi-asserted-by":"crossref","DOI":"10.3892\/etm.2021.9703","article-title":"Neurobiology of sleep","volume":"21","author":"Falup-Pecurariu","year":"2021","journal-title":"Exp Ther Med"},{"issue":"6","key":"10.1016\/j.jsmc.2025.06.004_bib7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/jnnp.73.6.629","article-title":"The Parkinson\u2019s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson\u2019s disease","volume":"73","author":"Chaudhuri","year":"2002","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.jsmc.2025.06.004_bib8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/bs.irn.2017.05.033","article-title":"Sleep dysfunction in Parkinson\u2019s disease","volume":"133","author":"Falup-Pecurariu","year":"2017","journal-title":"Int Rev Neurobiol"},{"issue":"16","key":"10.1016\/j.jsmc.2025.06.004_bib9","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1080\/14656566.2024.2422004","article-title":"Pharmacological and non-pharmacological management of sleep disturbances in Parkinson\u2019s disease: if when and how","volume":"25","author":"Falup-Pecurariu","year":"2024","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.jsmc.2025.06.004_bib10","author":"Chaudhuri"},{"issue":"1","key":"10.1016\/j.jsmc.2025.06.004_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41386-019-0448-y","article-title":"Sleep in Parkinson\u2019s disease","volume":"45","author":"Stefani","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.jsmc.2025.06.004_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jsmc.2016.10.011","article-title":"The cost of insomnia and the benefit of increased access to evidence-based treatment","volume":"12","author":"Reynolds","year":"2017","journal-title":"Sleep Medicine Clinics"},{"issue":"3","key":"10.1016\/j.jsmc.2025.06.004_bib13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s40675-017-0079-y","article-title":"Sleep and circadian rhythm disorders in Parkinson\u2019s disease","volume":"3","author":"Gros","year":"2017","journal-title":"Curr Sleep Med Rep"},{"issue":"2","key":"10.1016\/j.jsmc.2025.06.004_bib14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3390\/jpm12020322","article-title":"Personalized assessment of insomnia and sleep quality in patients with parkinson\u2019s disease","volume":"12","author":"Diaconu","year":"2022","journal-title":"J Personalized Med"},{"issue":"6","key":"10.1016\/j.jsmc.2025.06.004_bib15","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","article-title":"Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-Month, single-arm, open-label, phase 3 study","volume":"12","author":"Aldred","year":"2023","journal-title":"Neurol Ther"},{"issue":"10","key":"10.1016\/j.jsmc.2025.06.004_bib16","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.3390\/s24103045","article-title":"Parkinson\u2019s kinetigraph for wearable sensor detection of clinically unrecognized early-morning akinesia in Parkinson\u2019s disease: a case report-based observation","volume":"24","author":"Pop\u0142awska-Domaszewicz","year":"2024","journal-title":"Sensors"},{"issue":"1","key":"10.1016\/j.jsmc.2025.06.004_bib17","first-page":"e2352177","article-title":"Neurostimulation for advanced parkinson disease and quality of life at 5 years","volume":"7","author":"Jost","year":"2024","journal-title":"PubMed"},{"issue":"42","key":"10.1016\/j.jsmc.2025.06.004_bib18","article-title":"The treatment of sleep disorders in Parkinson\u2019s disease: from research to clinical practice","volume":"8","author":"Loddo","year":"2017","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.jsmc.2025.06.004_bib19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23441","article-title":"Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER)","volume":"26","author":"Trenkwalder","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.jsmc.2025.06.004_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/1877718X241306711","article-title":"Opicapone for Parkinson\u2019s disease-related sleep disturbances: the OASIS clinical trial","author":"Ferreira","year":"2025","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"10.1016\/j.jsmc.2025.06.004_bib21","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26067","article-title":"EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease","volume":"30","author":"Martinez-Martin","year":"2015","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.jsmc.2025.06.004_bib22","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3233\/JPD-225105","article-title":"Levodopa carbidopa intestinal gel in advanced Parkinson\u2019s disease: DUOGLOBE final 3-Year results","volume":"13","author":"Ray Chaudhuri","year":"2023","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.jsmc.2025.06.004_bib23","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.clinph.2022.01.112","article-title":"P 81 ELEGANCE \u2013 a prospective non-interventional study of the long-term effectiveness and safety of levodopa\u2013entacapone\u2013carbidopa intestinal gel (LECIG) in patients with advanced Parkinson\u2019s disease in routine care","volume":"137","author":"Jost","year":"2022","journal-title":"Clin Neurophysiol"},{"issue":"18_supplement","key":"10.1016\/j.jsmc.2025.06.004_bib24","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.98.18_supplement.2682","article-title":"Safety and efficacy of 24-Hour\/Day subcutaneous infusion of foslevodopa\/foscarbidopa in advanced Parkinson\u2019s disease during a phase 3 study: 6-month interim results (S16.009)","volume":"98","author":"Aldred","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.jsmc.2025.06.004_bib25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.sleep.2016.01.016","article-title":"Rotigotine May improve sleep architecture in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled polysomnographic study","volume":"21","author":"Pierantozzi","year":"2016","journal-title":"Sleep Med"},{"issue":"1","key":"10.1016\/j.jsmc.2025.06.004_bib26","article-title":"Rotigotine transdermal patch and sleep in Parkinson\u2019s disease: where are we now?","volume":"3","author":"Rosa-Grilo","year":"2017","journal-title":"npj Parkinson\u2019s Dis"},{"issue":"2","key":"10.1016\/j.jsmc.2025.06.004_bib27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson\u2019s Disease\u2014an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.jsmc.2025.06.004_bib28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3233\/JPD-2011-11037","article-title":"Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson\u2019s disease compared to conventional therapy: a real life study of non motor effect","volume":"1","author":"Martinez-Martin","year":"2011","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.jsmc.2025.06.004_bib29","doi-asserted-by":"crossref","unstructured":"De Cock VC, Dodet P, Leu-Semenescu S, et al. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson\u2019s disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study. Lancet Neurol. 2022;21(5):428-437.","DOI":"10.1016\/S1474-4422(22)00085-0"},{"issue":"7","key":"10.1016\/j.jsmc.2025.06.004_bib30","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3233\/JPD-223295","article-title":"Effects of levodopa-carbidopa intestinal gel on dyskinesia and non-motor symptoms including sleep: results from a meta-analysis with 24-Month Follow-Up","volume":"12","author":"Chaudhuri","year":"2022","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.jsmc.2025.06.004_bib31","article-title":"Improved sleep correlates with improved quality of life and motor symptoms with foslevodopa\/foscarbidopa","author":"Ray Chaudhuri","year":"2024","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"10.1016\/j.jsmc.2025.06.004_bib32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00415-006-0390-x","article-title":"Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson\u2019s disease","volume":"254","author":"Medeiros","year":"2007","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.jsmc.2025.06.004_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1532-5415.2007.01543.x","article-title":"Melatonin and bright-light treatment for rest\u00e2\u20ac\u201cactivity disruption in institutionalized patients with Alzheimer\u2019s disease","volume":"56","author":"Dowling","year":"2008","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"10.1016\/j.jsmc.2025.06.004_bib34","doi-asserted-by":"crossref","first-page":"487","DOI":"10.5664\/jcsm.27286","article-title":"Clinical guideline for the evaluation and management of chronic insomnia in adults","volume":"4","author":"Schutte-Rodin","year":"2008","journal-title":"J Clin Sleep Med"},{"issue":"11","key":"10.1016\/j.jsmc.2025.06.004_bib35","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/mds.23168","article-title":"Treatment of insomnia in Parkinson\u2019s disease: a controlled trial of eszopiclone and placebo","volume":"25","author":"Menza","year":"2010","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.jsmc.2025.06.004_bib36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.sleep.2010.10.004","article-title":"Pimavanserin tartrate, a 5-HT2A receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers","volume":"12","author":"Ancoli-Israel","year":"2011","journal-title":"Sleep Med"},{"issue":"11","key":"10.1016\/j.jsmc.2025.06.004_bib37","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1016\/j.clinthera.2016.09.010","article-title":"Review of safety and efficacy of sleep medicines in older adults","volume":"38","author":"Schroeck","year":"2016","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.jsmc.2025.06.004_bib38","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-Month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"6","key":"10.1016\/j.jsmc.2025.06.004_bib39","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/JCP.0000000000000404","article-title":"Agomelatine for depression in parkinson disease","volume":"35","author":"Avila","year":"2015","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jsmc.2025.06.004_bib40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ucl.2024.02.005","article-title":"Sleep and overactive bladder in Parkinson\u2019s disease","volume":"51","author":"Zheng","year":"2024","journal-title":"Urol Clin"},{"issue":"7","key":"10.1016\/j.jsmc.2025.06.004_bib41","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3390\/jpm13071053","article-title":"Nocturia and sleep in Parkinson\u2019s disease","volume":"13","author":"\u015etefania","year":"2023","journal-title":"J Personalized Med"},{"key":"10.1016\/j.jsmc.2025.06.004_bib42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.parkreldis.2018.07.005","article-title":"Mirabegron in patients with Parkinson disease and overactive bladder symptoms: a retrospective cohort","volume":"57","author":"Peyronnet","year":"2018","journal-title":"Parkinsonism Relat Disorders"},{"key":"10.1016\/j.jsmc.2025.06.004_bib43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.parkreldis.2018.12.002","article-title":"Use of botulinum toxin in Parkinson\u2019s disease","volume":"59","author":"Jocson","year":"2018","journal-title":"Parkinsonism Relat Disorders"},{"key":"10.1016\/j.jsmc.2025.06.004_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.sleep.2017.11.1126","article-title":"Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs Syndrome\/Willis-Ekbom disease in adults and children: an IRLSSG task force report","volume":"41","author":"Allen","year":"2017","journal-title":"Sleep Med"},{"issue":"7","key":"10.1016\/j.jsmc.2025.06.004_bib45","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.mayocp.2020.12.026","article-title":"The management of restless legs syndrome: an updated algorithm","volume":"96","author":"Silber","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.jsmc.2025.06.004_bib46","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1474-4422(13)70239-4","article-title":"Prolonged release oxycodone\u2013naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension","volume":"12","author":"Trenkwalder","year":"2013","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.jsmc.2025.06.004_bib47","doi-asserted-by":"crossref","DOI":"10.1007\/s11940-019-0596-8","article-title":"Therapies for restless legs in Parkinson\u2019s disease","volume":"21","author":"Cochen De Cock","year":"2019","journal-title":"Curr Treat Options Neurol"},{"issue":"3","key":"10.1016\/j.jsmc.2025.06.004_bib48","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1600-0404.1999.tb00732.x","article-title":"Nocturnal subcutaneous apomorphine infusion in Parkinson\u2019s disease and restless legs syndrome","volume":"100","author":"Reuter","year":"2009","journal-title":"Acta Neurol Scand"}],"container-title":["Sleep Medicine Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556407X25000372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556407X25000372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:42:45Z","timestamp":1772890965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556407X25000372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1556407X25000372"],"URL":"https:\/\/doi.org\/10.1016\/j.jsmc.2025.06.004","relation":{},"ISSN":["1556-407X"],"issn-type":[{"value":"1556-407X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Management of Insomnia in Parkinson\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsmc.2025.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}